Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
10:30pm, Thursday, 05'th Jan 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a
Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?
04:30pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?
12:48pm, Thursday, 08'th Dec 2022
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
04:08pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
12:48pm, Wednesday, 07'th Dec 2022
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
11:00am, Tuesday, 06'th Dec 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental
Zacks.com featured highlights include Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions.
01:58pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions are part of the Zacks Screen of the Week article.
4 Toxic Stocks More So Hazardous Amid Volatile Times
12:22pm, Wednesday, 30'th Nov 2022 Zacks Investment Research
Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a fe
4 Toxic Stocks More So Hazardous Amid Volatile Times
09:02am, Wednesday, 30'th Nov 2022
Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a fe
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
10:19am, Tuesday, 15'th Nov 2022 Benzinga
Gainers
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus contin
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
11:30am, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies Emergent partners with the Armed Forces Research
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
10:12am, Thursday, 10'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target
06:19pm, Wednesday, 09'th Nov 2022 Benzinga
Emergent BioSolutions Inc's (NYSE: EBS) Q3 sales fell 27% Y/Y to $240 million, missing the consensus of $268.30 million.
Revenues from CDMO services decreased $76.4 million, largely due to lower com
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
05:33pm, Wednesday, 09'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
03:47pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
